FindTrial
Sign In

Immunomodulatory effect of linezolid on central nervous system infection

Immunomodulatory effect of linezolid on central nervous system infection

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000037416
Enrollment
Unknown
Registered
2020-08-28
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Central nervous system Infection

Interventions

LZD group:Adjust the treatment when the drug concentration is abnormal or Adverse reactions occurred
non LZD group:none

Sponsors

Huashan Hospital, Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
14 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1) Adults Patients aged >=14 years; 2) Acute onset, onset time <=14 days; 3) The diagnosis of central nervous system infection is confirmed by clinical symptoms, signs, laboratory examination, imaging examination and etiology examination; 4) Informed consent of patients.

Exclusion criteria

Exclusion criteria: 1) the diagnosis of central nervous system infection is excluded by clinical symptoms, signs, laboratory examination, imaging examination and etiological examination; 2) patients lack of clinical infection and laboratory evaluation indicators, and could not be evaluated for efficacy and safety; 3) recently participated in other clinical trials Experimenter.

Design outcomes

Primary

MeasureTime frame
IL-6;TNF-a;IFN-gama;IL-12p70;IL-2;IL-4;IL-8;IL-10;IL-13;IL-1 beta;Blood concentration of linezolid;Linezolid concentration in cerebrospinal fluid;—

Countries

China

Contacts

Public ContactMinjie Yang

Huashan Hospital, Fudan University

tracy_yang99@hotmail.com+86 13917264461

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026